omniture
logo
Search
科州医药KECHOW PHARMA
Media Room

Latest News

rss

KeChow Pharma Announces NMPA Approval of Tunlametinib (HL-085) as the First Targeted Therapy for Patients with NRAS Mutated Advanced Melanoma and Previously Treated with PD-1/PD-L1

-- Tunlametinib is poised to be a potential best-in-class MEK inhibitor based on positive data from...

2024-03-18 18:02 1214

Roche and KeChow Reach a Cooperation Agreement

SHANGHAI, Aug. 20, 2021 /PRNewswire/ -- On August 2, 2021, Shanghai Roche Pharmaceuticals Co., Ltd....

2021-08-20 23:00 2788